Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Mexico Tech Monitor.
Press releases published on April 2, 2025
ProMOS Adopts Silvaco Victory TCAD Solution for the Development of Next-Gen Silicon Photonics Devices
GlobeNewswire
·
April 2, 2025
SANTA CLARA, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Silvaco Group, Inc. (Nasdaq: SVCO) (“Silvaco” or the “Company”), a provider of TCAD, EDA software and SIP solutions that enable semiconductor design and digital twin modeling through AI software and …
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
GlobeNewswire
·
April 2, 2025
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy …
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
GlobeNewswire
·
April 2, 2025
EMERYVILLE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA”; NASDAQ: XOMA), the biotech royalty aggregator, announced today Chief Investment Officer, Brad Sitko, will be a featured presenter at the Jones Healthcare and …
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
GlobeNewswire
·
April 2, 2025
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, …
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
GlobeNewswire
·
April 2, 2025
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer …
Grove AI Welcomes Former Novartis, UCB, and Google Executives to Company Advisory Board
GlobeNewswire
·
April 2, 2025
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Grove AI, pioneer in life science automation using agentic AI, today announced the formation of its inaugural Advisory Board. Comprised of prominent leaders from pharmaceutical and technology sectors, the …
Moringa: Learn Why These Moringa Powder Supplements Are Transforming Energy, Immunity, and Overall Health
GlobeNewswire
·
April 2, 2025
LAS VEGAS, April 02, 2025 (GLOBE NEWSWIRE) -- Moringa Oleifera, often called the “Miracle Tree,” is rapidly gaining recognition in the U.S. as a superfood for its remarkable health benefits. From boosting daily energy levels to fortifying immune support, …
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewswire
·
April 2, 2025
FREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapies for the treatment of autoimmune diseases, today announced the granting of …
Building on Past Success, Incident IQ Names Ryan Zeek as Chief Financial Officer
GlobeNewswire
·
April 2, 2025
ATLANTA, April 02, 2025 (GLOBE NEWSWIRE) -- Incident IQ, the leading workflow management platform built specifically to streamline K-12 school districts, has announced the appointment of Ryan Zeek as Chief Financial Officer. Ryan steps into the role after …
SchoolAI Secures $25 Million to Help Teachers and Schools Reach Every Student
GlobeNewswire
·
April 2, 2025
LEHI, Utah, April 02, 2025 (GLOBE NEWSWIRE) -- SchoolAI, a leading AI platform for teaching and learning, today announced it has closed $25 million in Series A funding to tackle education’s fundamental challenge: helping teachers provide personalized …
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment
GlobeNewswire
·
April 2, 2025
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment First subjects dosed in double-blind, placebo-controlled trial assessing AT-7687’s safety, tolerability, …
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
GlobeNewswire
·
April 2, 2025
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of …
Tilray Shifts Cultivation of its Flagship Canadian Cannabis Brand and Strain, Good Supply Jean Guy, to Masson-Angers Facility in Québec
GlobeNewswire
·
April 2, 2025
MASSON-ANGERS, Quebec, April 02, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., company (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of beverage, cannabis and wellness industries, and a leader …
Tilray Transfère la Culture de Sa Marque et de Sa Variété Canadienne Emblématique, Good Supply Jean Guy, à son Installation de Masson-Angers au Québec
GlobeNewswire
·
April 2, 2025
MASSON-ANGERS, Québec, 02 avr. 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (« Tilray ») (Nasdaq : TLRY ; TSX : TLRY), un leader mondial des biens de consommation, de l’industrie du cannabis, des boissons et du bien-être, ainsi qu'un acteur clé sur le …
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
GlobeNewswire
·
April 2, 2025
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, …
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
GlobeNewswire
·
April 2, 2025
NEWTON, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer …
Lantronix Named to CRN 2025 Internet of Things 50 List
GlobeNewswire
·
April 2, 2025
IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for IoT solutions enabling Edge AI Intelligence, today announced it has been recognized on the 2025 Internet of Things (IoT) 50 …
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025
GlobeNewswire
·
April 2, 2025
During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical Global Impression of Change (CGIC) …
Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference
GlobeNewswire
·
April 2, 2025
CHATHAM, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman M.D., …
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases
GlobeNewswire
·
April 2, 2025
The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery engine generated a drug discovery program to this previously undruggable target Nurix received a $15 …